CereMetrix Silver will feature advanced neuroimaging capabilities
that automatically pinpoints and quantifies brain function down to the
a subsidiary of CereHealth Corp., has received 510(k) clearance from the U.S.
Food and Drug Administration (FDA) for its neuroimaging analytics
and quantification platform CereMetrix Silver. Providers will now have
access to objective neuroimaging that detects, quantifies and analyzes
brain function down to the voxel level.
Silver image viewer is available to analyze brain imaging, including
PET, SPECT, MRI and CT scans. The platform is designed to increase
productivity and accuracy by providing reading physicians with
significant workflow efficiencies, including automated cluster analysis
that allows for quantitative and statistical analysis of SPECT brain
scans by comparing to other registered SPECT brain scans. The
proprietary workflow also features an automated reporting capabilities.
With CereMetrix Silver, reading physicians can now allow for the
localization and definition of brain function and differentiate between
hyper (more than average) and hypo (less than average) function in the
brain. Within viewports, the reading doctor can process and display the
brain image data in traditional two-dimensional formats, while
simultaneously displaying pseudo three-dimensional renderings.
With the current technology, functional brain imaging results are
blended across entire anatomical areas, allowing far more subjectivity
in the physician's interpretation and findings, said Shane Quint, Chief
Technology Officer of CereScan. CereMetrix Silver provides voxel-level
measurements to help physicians objectively analyze the imaging, and
make faster diagnostic decisions without compromising value-based care.
CereMetrix Silver is to be used by trained medical professionals as a
tool to aid in the evaluation and information management of digital
medical images. The neuroimaging platform will also aid in the
assessment of qSPECT (quantitative Single-Photon Emission Computed
Tomography) brain scans. The brain imaging data, once reconstructed,
will be mapped to a common brain template and anatomical map before
applying a clustering algorithm to group pixels/voxels of tissue with
deviations from average into clusters.
Technological advancements in radiology, such as the automated image
quantification and statistical analysis provided by CereMetrix, bring
the promise of better, faster patient care to millions affected by
complex brain-based disorders, said John Kelley, Chairman and Chief
Executive Officer of CereScan. Receiving FDA 510(k) clearance marks
the first wave of innovation we are excited to bring to the market.
CereMetrix's patented, statistically correlated, normative and scalable
medical database is designed to help improve the way complex brain
disorders are diagnosed and treated by providing researchers and medical
practitioners with quantitative imaging data and clinical information
analysis. The ever-expanding data warehouse includes thousands of scan
encounters, including patients medical histories, family histories,
symptoms, prior treatments, incoming diagnoses, outgoing diagnoses and
brain scan data. Additional information about CereMetrix can be found
CereMetrixis a registered mark of CereHealth Corp.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005966/en/
Jeff Kelley, 303-954-4953
Source: CereHealth Corp.